Cargando…
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment
BACKGROUND: Tenofovir (TDF) can cause kidney injury through tubular dysfunction, with or without drop of estimated glomerular filtration rate (eGFR). Whether mild eGFR reductions during treatment should be considered a reason for prompt TDF discontinuation, however, remains unclear. METHODS: Patient...
Autores principales: | Lapadula, Giuseppe, Bernasconi, Davide Paolo, Casari, Salvatore, Maggiolo, Franco, Cauda, Roberto, Di Pietro, Massimo, Ladisa, Nicoletta, Sighinolfi, Laura, Dal Zoppo, Sarah, Sabbatini, Francesca, Soria, Alessandro, Pezzoli, Chiara, Mondi, Annalisa, Costarelli, Silvia, Valsecchi, Maria Grazia, Torti, Carlo, Gori, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025011/ https://www.ncbi.nlm.nih.gov/pubmed/27632369 http://dx.doi.org/10.1371/journal.pone.0162320 |
Ejemplares similares
-
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
por: Costarelli, Silvia, et al.
Publicado: (2016) -
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function
por: Postorino, Maria Concetta, et al.
Publicado: (2016) -
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
por: Motta, Davide, et al.
Publicado: (2012) -
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014) -
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART
por: Lapadula, Giuseppe, et al.
Publicado: (2015)